156 related articles for article (PubMed ID: 37444389)
21. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
Neeser A; Ramasubramanian R; Wang C; Ma L
Immunooncol Technol; 2023 Sep; 19():100385. PubMed ID: 37483659
[TBL] [Abstract][Full Text] [Related]
22. B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers.
Ventin M; Cattaneo G; Maggs L; Jia J; Arya S; Ferrone S; Wang X; Ferrone CR
Front Oncol; 2023; 13():1193963. PubMed ID: 37483496
[TBL] [Abstract][Full Text] [Related]
23. INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.
Myers RM; Jacoby E; Pulsipher MA; Pasquini MC; Grupp SA; Shah NN; Laetsch TW; Curran KJ; Schultz LM
Transplant Cell Ther; 2023 Oct; 29(10):598-607. PubMed ID: 37481241
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor T cells for acute myeloid leukemia.
Fetsch V; Zeiser R
Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
[TBL] [Abstract][Full Text] [Related]
25. Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome.
Salz L; Seitz A; Schäfer D; Franzen J; Holzer T; Garcia-Prieto CA; Bürger I; Hardt O; Esteller M; Wagner W
Leukemia; 2023 Sep; 37(9):1868-1878. PubMed ID: 37452103
[TBL] [Abstract][Full Text] [Related]
26. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.
Yu T; Luo C; Zhang H; Tan Y; Yu L
Front Immunol; 2023; 14():1139482. PubMed ID: 37449207
[TBL] [Abstract][Full Text] [Related]
27. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Bücklein V; Perez A; Rejeski K; Iacoboni G; Jurinovic V; Holtick U; Penack O; Kharboutli S; Blumenberg V; Ackermann J; Frölich L; Johnson G; Patel K; Arciola B; Mhaskar R; Wood A; Schmidt C; Albanyan O; Gödel P; Hoster E; Bullinger L; Mackensen A; Locke F; von Bergwelt M; Barba P; Subklewe M; Jain MD
Hemasphere; 2023 Aug; 7(8):e907. PubMed ID: 37449196
[TBL] [Abstract][Full Text] [Related]
28. Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T-cell subsets and immunophenotypes in cancer patients.
Salem AM; Mugundu GM; Singh AP
CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1285-1304. PubMed ID: 37448297
[TBL] [Abstract][Full Text] [Related]
29. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
30. B7-H3 Associates with IMPDH2 and Regulates Cancer Cell Survival.
Alhamad S; Elmasry Y; Uwagboe I; Chekmeneva E; Sands C; Cooper BW; Camuzeaux S; Salam A; Parsons M
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444640
[TBL] [Abstract][Full Text] [Related]
31. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Vainstein V; Avni B; Grisariu S; Kfir-Erenfeld S; Asherie N; Nachmias B; Auman S; Saban R; Zimran E; Assayag M; Filanovsky K; Horowitz NA; Lebel E; Shaulov A; Gur M; Rosenbluh C; Krichevsky S; Stepensky P; Gatt ME
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444582
[TBL] [Abstract][Full Text] [Related]
32. Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance.
Eckerdt F; Platanias LC
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444568
[TBL] [Abstract][Full Text] [Related]
33. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.
Aureli A; Marziani B; Venditti A; Sconocchia T; Sconocchia G
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444456
[TBL] [Abstract][Full Text] [Related]
34. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
35. Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas.
Trieu V; Maida AE; Qazi S
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539537
[TBL] [Abstract][Full Text] [Related]
36. Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells.
Parodi M; Centonze G; Murianni F; Orecchia P; Andriani F; Roato I; Gardelli C; Balsamo M; Moro M; Taiè G; Pastorino U; Petretto A; Lavarello C; Milione M; Sozzi G; Roz L; Vitale M; Bertolini G
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458638
[TBL] [Abstract][Full Text] [Related]
37. B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma.
Bottino C; Vitale C; Dondero A; Castriconi R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444389
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
39. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
40. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
